Aluminum In Vaccines

America's Vaccine Safety Watchdog
VIC Home & Learning Center
Aluminum In Vaccines

  1. Material Safety Data Sheet: It is not possible to provide an MSDS for aluminum in vaccines because the exact nature of the adjuvant is known only to the vaccine maker, who may "temper" or treat the adjuvant in order to alter its solubility or other characteristics.  This information is considered by the FDA to be a trade secret.

  2. Comparative Toxicogenomics Database: explore Aluminum and conditions associated with exposure 

  3. Is Aluminum the New Thimerosal? by Dr. Robert Sears (full article  added 12/23/2010)

  4. European Journal of Pediatrics (abstract  added 01/10/2011):
    Rare cases of persistent pruritic nodules, sometimes associated with aluminium (Al) allergy, have been reported after the use of several Al adsorbed vaccines. During vaccine trials in the 1990s a high incidence of pruritic nodules (645 cases/76,000 recipients), in 77% associated with Al allergy, was observed after the administration of diphtheria-tetanus / acellular pertussis (DT/aP) vaccines from a single producer. In the present report 19 children with pruritic nodules after vaccination with Al hydroxide-adsorbed DTaP/polio+Hib (Infanrix, Pentavac) are described. The children had intensely itching nodules at the injection site, often aggravated during upper respiratory tract infections, and local skin alterations. So far, the symptoms have persisted for up to 7 years. The median time between vaccination and onset of symptoms was 1 month. 16 children were epicutaneously tested for Al, all with positive reactions indicating delayed hypersensitivity to Al. The condition is not commonly known but is important to recognise, as the child and the family may suffer considerably. Future vaccinations with Al-adsorbed vaccines may cause aggravation of the symptoms and the Al allergy. Al-containing skin products, such as antiperspirants, may cause contact dermatitis. Nodules may be mistaken for tumours. Even though the incidence of itching nodules and Al allergy after administration of Infanrix, Pentavac and other Al-adsorbed vaccines is probably low, research to replace Al adjuvants seems appropriate. We conclude that intensely itching subcutaneous nodules, lasting for many years, and hypersensitivity to aluminium may occur after DTaP/polio+Hib vaccination of infants.

  5. Neurochemical Research (full article  added 9/14/2010): 
    The persistent alterations of brain opioid systems ensuing from early life exposure to Thimerosal is just one element of a plethora of neurodevelopmental pathologies induced by this mercurial in animals and humans [6-9,11]. Its harmful effects are likely to be augmented by other vaccine adjuvants, such as aluminum, formaldehyde or antibiotics, and by various environmental toxins [31,43,44].

    Particularly aluminum compounds, added to vaccines to augment their immunogenicity, have been shown to synergistically potentiate Thimerosal's neurotoxicity [43]. Thus in the presence of other toxins or substances, which per se may be rather innocuous, even small doses of THIM in vaccines can lead to neurological injury in vulnerable children.

    In conclusion, this study documents that parenteral administration of Thimerosal to suckling rats at doses equivalent to those used in pediatric vaccines or higher produces lasting alterations of MORs in several brain regions and damage to neurons.

    If analogous changes occur in the brains of some children, they are likely to have profound neurological,physiological and behavioral consequences, which may be relevant for certain neurodevelopmental disorders. These data argue for removal of Thimerosal from all infant vaccines.
  6. Agency for Toxic Substances & Disease Registry (CDC): This fact sheet answers the most frequently asked health questions about aluminum.

  7. American Academy of Pediatrics: Aluminum is now being implicated as interfering with a variety of cellular and metabolic processes in the nervous system and in other tissues.  (Read entire article)

  8. Center for Disease Control and Prevention (CDC): The adjuvant aluminum is present in U.S. childhood vaccines that prevent hepatitis A, hepatitis B, diphtheria-tetanus-pertussis (DTaP, Tdap) Haemophilus influenzae type b (Hib), human papillomavirus (HPV) and pneumococcus infection. This adjuvant has been used safely in vaccines for decades.  (Read more)

  9. Food and Drug Administration: Aluminum adjuvant containing vaccines have a demonstrated safety profile of over six decades of use and have only uncommonly been associated with severe local reactions. Of note, the most common source of exposure to aluminum is from eating food or drinking water.  (Read more from the FDA about Common Ingredients in U.S. Licensed Vaccines)

  10. Journal of Inorganic Biochemistry: Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration.  (Read entire article)

  11. Journal of Toxicology and Environmental Health:  The growing bone is a particular target for aluminium in infants and young children (Koo & Kaplan, 1988). A 3-month old premature infant developed rickets after 6 weeks of therapy with an aluminium containing antacid (Pattaragarn & Alon, 2001).  p.201  (Read entire article)

  12. Conference report; Workshop summary; Aluminum in vaccines:   There seems to be abundant data concerning risk levels for ingested aluminum, but scant data about risk levels for injected aluminum…The uncertainties notwithstanding, there appeared to be a large margin of safety for aluminum adjuvants.  (Read entire article)